ENTA240719P12500
- 1.85
- 0.000.00%
Enanta Pharmaceuticals Newsroom
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution
Enanta Pharma Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Maintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline Potential
Enanta Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)
Analysts Are Bullish on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), Spruce Biosciences (SPRB)
Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), Enanta Pharmaceuticals (ENTA) and Synlogic (SYBX)
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), Enanta Pharmaceuticals (ENTA)
Buy Rating on Enanta Pharmaceuticals Amidst Promising RSV Program Developments and Strategic Expansion Into CSU Market
Enanta Pharma Analyst Ratings
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Enanta Pharmaceuticals (ENTA) and Arvinas Holding Company (ARVN)
Hold Rating on Enanta Pharmaceuticals: A Comprehensive Analysis of Future Prospects and Challenges
JMP Securities Maintains Outperform on Enanta Pharma, Lowers Price Target to $23
Enanta Pharma Analyst Ratings